Visual Acuity Outcome over Time in Non-Infectious Uveitis.

Michael Altaweel // Publications // Aug 18 2021

PubMed ID: 31821051

Author(s): Pistilli M, Joffe MM, Gangaputra SS, Pujari SS, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Sen HN, Suhler EB, Thorne JE, Bhatt NP, Foster CS, Begum H, Fitzgerald TD, Dreger KA, Altaweel MM, Holbrook JT, Kempen JH; Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Research Group. Visual acuity outcome over time in non-infectious uveitis. Ocul Immunol Inflamm. 2021 Aug 18;29(6):1064-1071. doi: 10.1080/09273948.2019.1687733. Epub 2019 Dec 10. PMID 31821051

Journal: Ocular Immunology And Inflammation, Volume 29, Issue 6, Aug 2021

Introduction: We evaluated visual acuity (VA) over 5 years in a subspecialty noninfectious uveitis population.Methods: Retrospective data from 5,530 noninfectious uveitis patients with anterior, intermediate, posterior or panuveitis were abstracted by expert reviewers. Mean VA was calculated using inverse probability of censoring weighting to account for losses to follow-up.Results: Patients were a median of 41 years old, 65% female, and 73% white. Initial mean VA was worse among panuveitis (20/84) than posterior (20/64), intermediate (20/47), and anterior (20/37) uveitides. On average, mean VA improved by 0.62, 0.51, 0.37, and 0.26 logMAR-equivalent lines over 2 years, respectively (each P < .001), then remained stable, except posterior uveitis mean VA worsened to initial levels.Conclusion: Mean VA of uveitic eyes improved and, typically, improvement was sustained under uveitis subspecialty care. Because VA tends to improve under tertiary care, mean VA change appears a better outcome for clinical studies than time-to-loss of VA.